This first edition of MDS ULTRA established its own identity – it honoured Morocco’s  and the MDS desert racing heritage ...

RYTELO® (imetelstat) net product revenue expected in the range of $220 to $240 million2026 total operating expenses expected in the range of ...

The Committee of Chief Medical Directors and Medical Directors of Federal Tertiary Hospitals (CCMDFTH) has called on health sector unions to embrace dialogue, industrial harmony, and collaboration for ...

Committee of Chief Medical Directors and Medical Directors of Federal Tertiary Hospitals (CCMDFTH) has called on health sector unions to embrace dialogue, industrial harmony and collaboration for the ...

Understanding MDS risk classification enhances patient care, focusing on tailored therapies and improving quality of life through effective treatment strategies. In clinical practice, patients with ...

An expert discusses how real-world evidence and patient-reported outcomes support luspatercept’s clinical benefits, while highlighting the high failure rates of ESA therapy in community practice. Real ...

Faron Pharmaceuticals (HEL:FARON)(LSE:FARN) - Strong efficacy and survival outcomes with bexmarilimab in high-risk MDS support Phase III advancement Median overall survival (mOS) of 13.4 months in r/r ...

Median overall survival of 13.4 months in 32 r/r MDS patients treated with bexmarilimab + azacitidine ORR of 63% and 72% observed in patients with r/r MDS (n=32) and frontline MDS patients (n=18), ...